Herein, we extend this analysis to several cohorts, comprising data of over 500 samples, and determine that GBM samples present overexpression of HDAC6 and that its high expression correlates with advanced glioma grade and poor patient survival. This evidence concerns the gene HDAC6 and central nervous system cancer.